NYSE:SYK
Stryker Corp. (SYK)
Financials 
Technical Analysis 
Aug 15, 2026, 12:00 amThis summary was created by AI, based on 8 opinions in the last 12 months.
Stryker Corp. (SYK) remains a leading player in the medical device sector, particularly in orthopedics, holding a significant market share in the U.S. With its robust robotics platform and the increasing demand driven by aging demographics, particularly in hip and knee replacements, the company shows strong potential for recovery from recent challenges, including a cybersecurity attack. Despite recent weaknesses in the broader medtech industry, many analysts express optimism around SYK's growth trajectory, with expectations of revenue and earnings per share advancing in the coming years. Additionally, Stryker's solid relationships with healthcare providers and a sticky business model (where surgeons tend to stick with suppliers) position it well for sustained success. However, some experts caution that while the stock may have long-term merits, the current investment climate may not be optimal.
It's a play on aging populations. It sold off on weakness in the medical device sectors, which is the time he bough it. He sees good growth.
(Analysts’ price target is $387.58)
Lyle Stein
He started buying this in 2021 when the stock got hammered during Covid, but recovered after it. SYK has been hammered this year because of overall weakness in the health sector. Also, SYK had a cybersecurity attack. SYK has the best relationships with doctors and is arguably the leader in medical devices. The valuation is attractive. Expects $15 EPS in 2027 at 20x PE. Is growing the topline 10%. The population is aging.
Main business is orthopedics, which is profitable for US hospitals. As artificial joints improve, more people opt for surgery rather than rehab. All of med tech in general has been weak (though he's not sure why).
Very well run. Consistently gaining market share from JNJ and ZBH. Cybersecurity incident in Q1, which impacted production. High quality. Revenue should grow high single digits for foreseeable future. Yield is 1.24%.
He hasn't seen valuations like this since 2020 briefly and 1993. Their big growth driver is orthopedics with robot-assisted surgeries, with growth expected to double over 5 years; robots account for roughly 45% of their orthopedics business.
(Analysts’ price target is $429.76)
Paul MacDonald5-year performance is 15%, creates returns on ROIC, well run, quality.
David DriscollDown along with the market. About 73% of revenues from US; rest is from other parts of the world, so lots of growth internationally. Very strong demographic play. Great company.
Paul Harris, CFA
It produces medical devices which is a good business to be in. The aging population needs their products and there is a backlog from Covid. Their products change the quality of life and reduce hospital stays to a couple of days. 71% of its business comes from the U.S. and there is lots of growth internationally.
Paul Harris, CFA
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Popular Articles
Stryker Corp. (SYK) Frequently Asked Questions
What is Stryker Corp. stock symbol?
Stryker Corp. is a American stock, trading under the symbol SYK (previously SYK-N on Stockchase) on the New York Stock Exchange (SYK). It is usually referred to as NYSE:SYK or SYK
Is Stryker Corp. a buy or a sell?
In the last year, 8 stock analysts issued a Buy, Sell, or Hold rating on SYK (previously SYK-N on Stockchase). 6 analysts recommended to BUY and 2 analysts recommended to SELL the stock. The latest stock analyst rating is TOP PICK. Read the latest stock experts' ratings for Stryker Corp..
Is Stryker Corp. a good investment or a top pick?
Stryker Corp. was recommended as a Top Pick by Christine Poole on 2026-08-11. Read the latest stock experts ratings for Stryker Corp..
Why is Stryker Corp. stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Stryker Corp..
Is Stryker Corp. worth watching?
Stryker Corp. is followed by 260 investors on Stockchase and is a trending stock that is worth watching.
What is Stryker Corp. stock price?
On 2026-08-14, Stryker Corp. (SYK) stock closed at a price of $339.21.
'%20fill='%23FFB800'%3e%3cg%20id='filled-.-button'%20transform='translate(120.000000,%20413.999972)'%3e%3cpath%20d='M101.499729,2.82302245e-05%20C102.285413,-0.00432461793%20103.254164,0.496634241%20103.645655,1.25173399%20L103.712109,1.39623206%20L105.747863,6.45331817%20L111.028779,6.80428588%20C111.60867,6.84282525%20112.147242,7.1236355%20112.517275,7.58038413%20C113.223405,8.45199453%20113.142035,9.72214747%20112.357105,10.4940033%20L112.234099,10.6059323%20L108.072656,14.10894%20L109.356339,19.592529%20C109.472157,20.0872738%20109.394126,20.6085551%20109.13883,21.0455786%20C108.624329,21.9263208%20107.536956,22.2447485%20106.649713,21.8010736%20L106.511398,21.7246573%20L101.5,18.7715858%20L96.4886024,21.7246573%20C95.5790916,22.2767096%2094.4027498,21.9726757%2093.8611695,21.0455786%20C93.6058745,20.6085551%2093.5278433,20.0872738%2093.6436608,19.592529%20L94.9273443,14.10894%20L90.7659013,10.6059323%20C89.8680707,9.85015912%2089.7412886,8.49557505%2090.4827254,7.58038413%20C90.8527577,7.1236355%2091.39133,6.84282525%2091.9712215,6.80428588%20L97.2521374,6.45331817%20L99.2878908,1.39623206%20C99.6240254,0.561228427%20100.665516,-0.00460395016%20101.499729,2.82302245e-05%20Z'%20id='top-picks-.-icon-copy-7'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e){kind=small}
'%20fill='%23EAEAEA'%3e%3cg%20id='filled-.-button'%20transform='translate(120.000000,%20413.999972)'%3e%3cpath%20d='M131.499729,2.82302245e-05%20C132.285413,-0.00432461793%20133.254164,0.496634241%20133.645655,1.25173399%20L133.712109,1.39623206%20L135.747863,6.45331817%20L141.028779,6.80428588%20C141.60867,6.84282525%20142.147242,7.1236355%20142.517275,7.58038413%20C143.223405,8.45199453%20143.142035,9.72214747%20142.357105,10.4940033%20L142.234099,10.6059323%20L138.072656,14.10894%20L139.356339,19.592529%20C139.472157,20.0872738%20139.394126,20.6085551%20139.13883,21.0455786%20C138.624329,21.9263208%20137.536956,22.2447485%20136.649713,21.8010736%20L136.511398,21.7246573%20L131.5,18.7715858%20L126.488602,21.7246573%20C125.579092,22.2767096%20124.40275,21.9726757%20123.86117,21.0455786%20C123.605874,20.6085551%20123.527843,20.0872738%20123.643661,19.592529%20L124.927344,14.10894%20L120.765901,10.6059323%20C119.868071,9.85015912%20119.741289,8.49557505%20120.482725,7.58038413%20C120.852758,7.1236355%20121.39133,6.84282525%20121.971221,6.80428588%20L127.252137,6.45331817%20L129.287891,1.39623206%20C129.624025,0.561228427%20130.665516,-0.00460395016%20131.499729,2.82302245e-05%20Z'%20id='top-picks-.-icon-copy-8'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e){kind=small}
Their robotics platform in medical devices has a 70% market share in the U.S., and has a recurring revenue stream. SYK feels it can make up for losses from the cyber attack by the end of the year. 75% of revenues are in the U.S. and 25% internationally. Will benefit from aging demographics (hip and knee replacement), but also shoulder and spine. Pays a 1% dividend which keeps increasing.
(Analysts’ price target is $384.08)